drugset / Trial / NCT06757010

A Study of NE3107 in Early Parkinson's

NCT06757010 ↗

Phase 2 Active not recruiting 60 enrolled BioVie Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants have when taking bezisterim? Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease. Participants will * have a physical examination that includes an electrocardiogram * take drug or placebo twice daily for four months * visit a clinical site or receive an at home visit seven times over the course of five months

Timeline

Start
2025-03-26
Primary completion
2026-05-01
Completion
2026-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject bezisterim Small molecule 20 mg Oral

Indications